Home > Comunicazione > Pubblicazioni > Pharmacogenetics of Capecitabine-based treatment in advanced breast cancer patients
Pharmacogenetics of Capecitabine-based treatment in advanced breast cancer patients
Genes for which polymorphisms may potentially influence inter-individual pharmacodynamics variation of fluoropyrimidines, including capecitabine, are the methylenetetrahydrofolate reductase (MTHFR) and the dihydropyrimidine dehydrogenase (DPYD).
The C677T and A1298C MTHFR polymorphisms may modulate the cytotoxic effect of 5-fluorouracil (5-FU), commonly used chemotherapeutic agents for breast cancer, because the modes of action of 5FU is critically dependent on cellular composition of folates.
The C677T and A1298C MTHFR polymorphisms are associated with reduced activity of MTHFR enzyme, resulting in increased levels of homocysteine and abnormal intracellular distribution of folates.
DOWNLOAD
